214 related articles for article (PubMed ID: 24269957)
1. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
[TBL] [Abstract][Full Text] [Related]
2. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
3. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
4. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
5. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
6. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
7. In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.
Schroeder JA; Chen Y; Fang J; Wilcox DA; Shi Q
J Thromb Haemost; 2014 Aug; 12(8):1283-93. PubMed ID: 24931217
[TBL] [Abstract][Full Text] [Related]
8. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
Shi Q; Wilcox DA; Fahs SA; Fang J; Johnson BD; DU LM; Desai D; Montgomery RR
J Thromb Haemost; 2007 Feb; 5(2):352-61. PubMed ID: 17269937
[TBL] [Abstract][Full Text] [Related]
9. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
10. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.
Chen Y; Schroeder JA; Kuether EL; Zhang G; Shi Q
Mol Ther; 2014 Jan; 22(1):169-77. PubMed ID: 24042561
[TBL] [Abstract][Full Text] [Related]
11. Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.
Gao C; Schroeder JA; Xue F; Jing W; Cai Y; Scheck A; Subramaniam S; Rao S; Weiler H; Czechowicz A; Shi Q
Blood Adv; 2019 Sep; 3(18):2700-2711. PubMed ID: 31515232
[TBL] [Abstract][Full Text] [Related]
12. Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells.
Jing W; Baumgartner CK; Xue F; Schroeder JA; Shi Q
J Thromb Haemost; 2023 Mar; 21(3):488-498. PubMed ID: 36696197
[TBL] [Abstract][Full Text] [Related]
13. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.
Cai Y; Shi Q
Front Immunol; 2020; 11():964. PubMed ID: 32595633
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
[TBL] [Abstract][Full Text] [Related]
15. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
16. Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.
Wang X; Fu RY; Li C; Chen CY; Firrman J; Konkle BA; Zhang J; Li L; Xiao W; Poncz M; Miao CH
Blood Adv; 2020 Nov; 4(22):5722-5734. PubMed ID: 33216891
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
19. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
Chen Y; Schroeder JA; Chen J; Luo X; Baumgartner CK; Montgomery RR; Hu J; Shi Q
Blood; 2016 Mar; 127(10):1346-54. PubMed ID: 26668132
[TBL] [Abstract][Full Text] [Related]
20. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
Kootstra NA; Matsumura R; Verma IM
Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
